2021-07-29

[#DIV28SUPER] Register for the APA Division 28 Live Event! - August 13th, 2021 1-3 ET

Register for the FREE live event here: https://jhmi.co1.qualtrics.com/jfe/form/SV_blwcEmYRaPk9qVU

Register for the Annual Convention here: https://convention.apa.org/

Cecilia Bergeria, Ph.D.
Assistant Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
P: 410-550-1979

2021-07-28

[#DIV28SUPER] Albert Bandura

In case you had not heard the news -- history of psych list just posted this news - Dr. Bandura died today at the age of 95.

Have not yet seen an official note from Stanford but this is out on popular media


----- Forwarded Message -----
From: Dr. Kate Harper <kharper@wlu.ca>


2021-07-23

[#DIV28SUPER] FW: USM Behavior & Addiction Research Lab PhD Virtual Open House

Dear Colleagues,

 

Hope you are enjoying your summer! I am seeking applications for our PhD program in counseling psych at Southern Miss for 2022 (deadline 12-1-21). As part of recruiting for the lab I will be hosting a few virtual open houses about the lab, our research focus and discuss applying to PhD programs in general. The information is below as well as a link to register for the first open house. We will discuss the structure of the lab, focus of our work, potential future directions, alumni achievements, and the opportunity to ask questions or me and some students. Please pass this information to any undergrad or master’s degree students you work with who are considering PhD programs and may be interested in learning more. Advanced registration is required! Thanks. Have a good day. Mike

 

BAR Lab Info Session

When: Jul 28, 2021 01:00 PM Central Time (US and Canada)

 

Register in advance for this meeting:

https://usm-edu.zoom.us/meeting/register/tZ0kdOmrqzooG9Om_blI1_4xY98N-mwK7Frr  

 

After registering, participants will receive a confirmation email containing information about joining the meeting.

 

Michael B. Madson, Ph.D.

Professor

School of Psychology

Associate Chair – USM Institutional Review Board

Undergraduate Program Coordinator

The University of Southern Mississippi

118 College Dr #5025

Hattiesburg, MS 39406

601-266-4546

Michael.madson@usm.edu

USM BAR Lab

Facebook Page

Twitter: @UsmBar

 

Click on this link to unsubscribe from the DIV50DISCUSS list UNSUBSCRIBE

An email will automatically open with "Unsubscribe" in the subject area. Just Send the message, as is, to unsubscribe from this list.

2021-07-20

[#DIV28M] RxP Designation Committee-Call for Nominations

Share as you see fit; sorry for any cross posting.


Nancy A. Piotrowski, Ph.D.
Council Representative, Society of Environmental, Population, & Conservation Psychology, Division 34, American Psychological Association
Treasurer/Past President/LAN Chair, Napa Solano Psychological Association
Trustee, California Psychological Association PAC
Commissioner, National Certification Commission for Addiction Professionals
 
MAIL:  P.O. Box 5525, Vallejo, California 94591-0552
With Offices in the San Francisco Bay Area
Office Phone:  707.561.2358
FAX by request
 
Email:              napiotrowski@yahoo.com    
ALT Email:       PiotrowskiConsultation@gmail.com
Skype:             napiotrowski
 

IMPORTANT NOTICE: This transmission and any attachments are intended only for the individual or entity to which it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable federal or state laws.  If the reader of this transmission is not the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this communication, without explicit written communication to handle otherwise, is strictly prohibited.  If you have received this transmission in error, please notify me immediately by email.


----- Forwarded Message -----
From: Aquino, Javier <jaquino@apa.org>

APA RxP Designation Committee Call for Nominations 

 

The American Psychological Association (APA) Board of Education Affairs (BEA) and the Board of Professional Affairs (BPA) are seeking nominations to fill two seats on the Designation Committee for Postdoctoral Education and Training Programs in Psychopharmacology for Prescriptive Authority (RxP Designation Committee). The appointees will serve a three-year term beginning January 1, 2022. Committee members shall meet once a year virtually in the fall and may work, as needed, throughout the year via email and conference calls. The primary task of the committee is to review applications from training programs in psychopharmacology seeking to be designated by the APA. 

 

The deadline for all nominations is Friday, September 3, 2021. If you are interested in serving on the committee, or know of someone else who would be qualified for this position, please send nominations, along with the below-described information, to Allison Gillens. Please note that nominators of other individuals are responsible for ensuring that these materials are submitted. 

 

Candidate Criteria 

We welcome nominations of individuals who have expertise in any of the following domains: 

  • Psychopharmacology postdoctoral program directors. 
  • Basic psychopharmacology science or clinical psychopharmacology research. 
  • Prescriptive authority in psychology. 
  • Prescriptive authority in another health care profession. 
  • Health care system quality assurance. 

 

Other areas of interest are developmental psychopharmacology, integrated health care systems, and ethnic/cultural factors that can influence psychopharmacological decision-making. The Committee is also interested in nominees with expertise in health inequities, dependence, and addiction.  

The RxP Designation Committee is composed of one public member seat and five member seats comprised of psychologists who are APA members. The Committee is seeking individuals that represents all aspects of APA's diverse membership including demographic diversity, diversity of career stage and various employment settings. Appointments to the committee are made jointly by BEA and BPA, and confirmed by the APA Board of Directors. Those appointed to the committee will be notified in writing. 

Nominees, if appointed, agree to dedicate the time necessary to fulfill their responsibility to the committee including but not limited to work between meetings, reviewing documents and applications, responding to requests from APA staff in a timely manner, and attendance at all meetings. 

 

Candidate Submission Materials 

  • Letter indicating the individual's willingness to serve if selected. 
  • 300-word description of qualifications as relates to the areas of expertise noted above. 
  • If applicable, indication that they qualify as an early career psychologist (ECP), psychologists who are within 10 years of the receipt of their doctoral degree. 
  • Current curriculum vita. 

 

 

Allison Gillens, MPS

Assistant Director, Professional Psychology Programs

Center for Education in Psychology 

Education Directorate

American Psychological Association

 

750 First Street NE, Washington DC 20002-4242

202-336-5775

 


2021-07-16

[#DIV28SUPER] NIDA Neuroscience Update July 16, 2021

Table of Contents

 

I.                   Addressing Health Disparities With Neuroscience Webinar:

II.                 RFA-DA-22-011 Large Scale Mapping and/or Molecular Profiling of Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain (R01 - Clinical Trial Not Allowed) 

III.              PAR-20-225  Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)

IV.              NOT-DA-20-030 Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders

 

 

 

I.                   Addressing Health Disparities With Neuroscience Webinar:

 

“July 23rd, 2021 from 11:30am-1:00pm EDT: The NIDA Division of Neuroscience and Behavior’s Diversity and Inclusion Group invites you to the virtual seminar Addressing Health Disparities With Neuroscience: “Social Environment and the Developing Brain”.  This new virtual seminar series brings together two scientists from disparate fields to discuss how basic, translational and clinical neuroscience research can inform, and be informed by, research on health disparities and health inequities.  The July 2021 seminar, Social Environment and the Developing Brain, will explore how social and environmental factors can act as important predictors of neurocognitive development, and will feature Dr. Kimberly Noble, M.D., Ph.D. (Teacher’s College, Columbia University) and Dr. Daniel Hackman, Ph.D. (USC Suzanne Dworak-Peck School of Social Work, University of Southern California).  Zoom registration link is available here.”

 

 

 

II.                 RFA-DA-22-011 Large Scale Mapping and/or Molecular Profiling of Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain (R01 - Clinical Trial Not Allowed)  https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-011.html   Application due date: October 15, 2021 due by 5:00 PM local time of applicant organization.

 

This funding opportunity announcement aims to support research that employs innovative scalable technologies to identify, map, and profile cellular ensembles and/or cell-types that produce and/or respond to opioids or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on single-cell resolution approaches that enable multimodal high-throughput functional mapping, anatomical characterization and molecular profiling of cell assemblies identified as targets of, or as primary sources of opioids in the brain.

This award uses a R01 mechanism with a budget cap of $700K direct cost per year. Multidisciplinary collaborative approaches are encouraged. This is a reissue of PAR-20-241 but new applications only are accepted.

 

Address inquiries to

satterleej@nida.nih.go

olivier.berton@nih.gov

 

 

III.              PAR-20-225  Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PAR-20-225.htmlApplication Due Dates: October 19, 2021, October 19, 2022 by 5:00 PM local time of applicant organization. All applications are due by 5:00 PM local time of applicant organization. 

 

 

Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.

The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

 

 

NOT-DA-20-030 Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-030.html

Application Due Dates:   Standard Due Dates Apply.

 

This Notice encourages applications for research projects that identify, validate and/or functionally characterize loci, genetic variations and haplotypes that are associated with vulnerability to addiction and that potentially inform the likelihood of responsiveness to treatment. Data may be collected from the general population, special populations, recent admixed populations, and/or electronic medical records (EMR). Secondary data analysis of data collected from the general population, special populations, recent admixed populations, and/or animal models is also appropriate for this notice. Investigators are encouraged to include functional characterization, gene x gene interactions, gene x environment interactions, and gene x environment x development interactions.

 

 

 The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-

 

 

[#DIV28SUPER] Fwd: [DIVTRIO] Big news re/psych science on the Hill!

Div 28 members,

See below for excellent news from Washington DC.  APA advocacy in action!!

-Ryan

___________________
Ryan Vandrey, Ph.D.
Professor
Behavioral Pharmacology Research Unit
Johns Hopkins University School of Medicine
5510 Nathan Shock Dr.
Baltimore, MD 21224
410-550-4036 (phone)
410-550-0030 (fax)




Begin forwarded message:

From: "Prinstein, Mitch" <MPrinstein@APA.ORG>
Subject: [DIVTRIO] Big news re/psych science on the Hill!
Date: July 16, 2021 at 10:57:19 AM EDT
Reply-To: APA Division Presidential trios communicating about divisional topics <DIVTRIO@LISTS.APA.ORG>


      External Email - Use Caution      



Dear Colleagues: 
 
We are writing to share an exciting APA update from the Hill. Yesterday, a bill was approved by the House Appropriations Committee.  This is a bill that APA's Advocacy team has been dedicating enormous effort towards since it has very important implications for psychological science.  
 
We are thrilled to report on three big successes in the bill that are a direct result of member advocacy this year through the APA 2021 Virtual Advocacy Summit Series. The House bill includes: 
 
  • $25 million for the Graduate Psychology Education (GPE) Program – an increase of $6 million over last year's enacted level 
  • $20.3 million for the Minority Fellowship Program (MFP) – an increase of $4.1 million over last year's enacted level
  • $49.8 million for the NIH's Office of Behavioral & Social Science Research (OBSSR) – an increase of $20 million over last year's enacted level
 
This increase in the House's FY22 LHHS-Ed bill comes as a direct result of our Stand for Science to Advance Psychology Advocacy Summit in May, in which more than 120 psychologists from 33 states met with their Congressional delegations to advocate for advances in legislation related to psychological science.
 
This bill will now move to the full House of Representatives. This is an important win and first step in the continued recognition of the value of behavioral research by Congress. Although the Senate has not indicated when it will begin consideration of its version of the bill, we will keep you updated as the FY22 appropriations process continues.
 
Thanks to so many of you who helped fight for psychological science and to many scientists who joined our advocacy efforts!  APA is excited for our ongoing work together to make our science, and the development of new scientists, top priorities in the US!
 
 
Katherine McGuire, APA Chief Advocacy Officer
Mitch Prinstein, Ph.D., APA Chief Science Officer
 
 
APA is proud to introduce Science Spotlight, a new newsletter for psychological scientists. Subscribe today!

 
 
 
Click on this link to unsubscribe from the DIVTRIO list UNSUBSCRIBE

An email will automatically open with "Unsubscribe" in the subject area. Just Send the message, as is, to unsubscribe from this list.


[#DIV28SUPER] Fwd: disseminating new alcohol training program info

All,

See below announcement and updated info regarding a funding opportunity for doctoral students from underrepresented populations interested in alcohol research.
Regards,

-Ryan

Begin forwarded message:


 
Dear Colleagues,
 
The deadline to apply for the inaugural cohort of the Enhancing Diversity in Alcohol Research (EDAR) training program is rapidly approaching! This two-year, fully virtual, NIAAA-sponsored training program is open to psychology doctoral trainees from underrepresented backgrounds (per NIH NOT-OD-20-031). No prior alcohol research experience is required. New prospective mentors have been added to our UPDATED EDAR Program Brochure. New information regarding the EDAR curriculum, trainee support, and eligibility are available on the EDAR Program Website.
 
Please also contact Dr. Julianne Flanagan (Director) or Ms. Jocelyn Rogers (Coordinator) with questions at EDAR@musc.edu.
 
Applications are due July 31, 2021 and include a brief online survey, a 1-2 page statement of interest, and current CV: Click here to apply to EDAR 
 
Please forgive cross-postings, and please share widely!
 
 
From: Flanagan, Julianne 
Sent: Monday, June 28, 2021 1:04 PM
To: Ryan Vandrey <rvandrey@jhmi.edu>
Cc: Kelly Dunn <kdunn9@jhmi.edu>
Subject: RE: disseminating new alcohol training program info
 
Wonderful, thanks so much!
 
Julianne
 
From: Ryan Vandrey <rvandrey@jhmi.edu> 
Sent: Monday, June 28, 2021 1:03 PM
To: Flanagan, Julianne <hellmuth@musc.edu>
Cc: Kelly Dunn <kdunn9@jhmi.edu>
Subject: Re: disseminating new alcohol training program info
 

CAUTION: External

This is great Julianne, thanks for sending!  Will forward to Div 28 asap.
 
-Ryan

 

On Jun 28, 2021, at 12:58 PM, Flanagan, Julianne <hellmuth@musc.edu> wrote:
 

      External Email - Use Caution      

 

 

Dear Drs. Dunn and Vandrey,
 
I'm writing to ask if you might be willing to share an announcement (included below) of a new, NIAAA-sponsored and diversity-focused training program with the APA Division 28 community? This is a 2 year, fully virtual program funded by an R25 mechanism. The program will provide mentorship, didactics, and financial support to psychology trainees from underrepresented minority backgrounds with the primary objective of helping URM trainees navigate the challenging internship and fellowship application process. We'd certainly like to ensure that Division 28 trainees are aware of the program, as quite a few of our available mentors have psychopharm and medication development expertise. No previous alcohol research experience is required, so if a trainee has previously been more focused on individuals with or at-risk for drug use disorders, that's perfectly acceptable! Applications are currently being accepted.
 
Please don't hesitate to reach out with any questions or concerns.
 
Thanks so much for considering,
 
Julianne
 
 
 
 
 
 
<image001.png>
Applications are currently being accepted for the inaugural cohort of the Enhancing Diversity in Alcohol Research (EDAR) training program! This two-year, fully virtual, NIAAA-sponsored training program is open to psychology doctoral trainees from underrepresented backgrounds (per NIH NOT-OD-20-031). No prior alcohol research experience is required! More details are available in our EDAR Program Brochure. Please also contact Dr. Julianne Flanagan (Director) or Ms. Jocelyn Rogers (Coordinator) with questions.
 
Applications are due July 31, 2021 and include a brief online survey, a 1-2 page statement of interest, and current CV: Click here to apply to EDAR 
 
*** Attention Faculty: Please contact us if you are interested in becoming a prospective EDAR mentor!***
 
 
 
Julianne C. Flanagan, Ph.D.
Licensed Clinical Psychologist
Associate Professor 
Addiction Sciences Division
Department of Psychiatry and Behavioral Sciences 
Medical University of South Carolina
Staff Psychologist, Ralph H. Johnson VAMC
Tel: 843 792 5569
She/her/hers (what's this?)

2021-07-15

[#DIV28SUPER] Postdoctoral Fellowship at Northern Kentucky University

A postdoctoral position is now available in the Developmental Autonomic Psychophysiology Laboratory at Northern Kentucky University. Ongoing research funded by NIAAA examines the effects of stress and substance use on young adults cardiovascular functioning.

Primary Responsibilities:
The post-doctoral fellow is encouraged to develop research studies and to contribute to ongoing projects by writing manuscripts and overseeing the work of undergraduate research assistants. The post-doctoral fellow will also have the opportunity to teach one course per semester (most likely Biopsychology, Psychopharmacology, or Research Methods).    

All applicants must submit: (1) CV and (2) 3 letters of reference electronically to Dr. Ty Brumback (brumbackt1@nku.edu). Review of applications will begin immediately and will continue until the position has been filled.  

See full job posting at: https://jobs.nku.edu/postings/10550
 
NKU seeks excellence by enriching its educational environment and culture through the diversity of its administration, faculty and staff and by embracing inclusiveness, equity, and global awareness in all dimensions of its work. NKU is an Equal Opportunity/Equal Access/Affirmative Action institution. Applications by members of diverse groups and by persons with a demonstrated commitment to issues of diversity and experience in achieving goals relative to inclusive excellence are encouraged.


Ty Brumback, Ph.D.
Assistant Professor

Northern Kentucky University

Department of Psychological Science
1 Nunn Drive, MEP 359
Highland Heights, KY  41099-2000
Phone: 859-572-1484

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

2021-07-12

[#DIV28SUPER] NIH Request for Information (RFI) on Streamlining Access to Controlled Data from NIH Data Repositories NOT-OD-21-157 Response needed by August 9, 2021

NIH Request for Information (RFI) on Streamlining Access to Controlled Data from NIH Data Repositories

Notice Number:

NOT-OD-21-157

Key Dates

Release Date:

July 9, 2021

Response Date:

August 09, 2021

Related Announcements

None

Issued by

Office of The Director, National Institutes of Health (OD)

Purpose

NIH is requesting input on strategies for harmonizing, simplifying, and streamlining mechanisms for accessing data in NIH-supported controlled-access data repositories that continue to uphold robust data privacy and security protections. In particular, NIH would like to understand better researchers' experiences in finding and accessing controlled access data housed in NIH-supported repositories and the extent to which existing NIH policies address aggregation and linkage of controlled access data.

This Notice is part of several NIH activities to engage stakeholders on this topic. Interested parties may find additional information at: https://datascience.nih.gov/streamlining-access-to-controlled-data.

Background

NIH stores and facilitates access to many datasets, both open and controlled, with the goal of accelerating new discoveries, thereby maximizing taxpayer return on investment in the collection of these datasets. Data derived from humans that are shared through controlled-access mechanisms in particular, reflect NIH's commitment to protect sensitive data from and honor the informed consent provided by research participants in NIH-supported studies.

NIH has supported multiple controlled-access data repositories that uphold appropriate data protections (for both human data and other sensitive data) while meeting the needs of various researcher communities. However, as data access requests increase, new repositories are established, and new mechanisms of providing access to data are developed, it is apparent that opportunities remain to improve efficiency and harmonization among repositories to make NIH-supported controlled-access data more Findable, Accessible, Interoperable, and Reusable (FAIR) and to ensure appropriate oversight when data from different resources are combined. While these trends are enabling datasets and datatypes to be combined in new ways that advance the science, datasets and datatypes that may or may not be controlled may, when combined, create inadvertent re-identification risks.

Request for Information

NIH is requesting input on issues that are relevant to users of NIH-supported controlled-access data repositories (hereinafter "repositories"). NIH notes that the scope of this RFI is intended to cover strategies generalizable to all NIH-supported controlled-access data repositories, and all data types featured therein and is not specific to particular data repositories. This RFI is not intended to identify specific repository access challenges, but rather to help NIH understand users' experiences and potentially workable solutions to streamlining access to controlled data. Prior RFIs sought community input on opportunities and challenges associated with particular repositories, (for example with dbGaP in 2017[1]).

While elements of this RFI touch on informed consent in the sense of ensuring a common understanding and vocabulary to describe how data may or may not be used, NIH has released another RFI on sample informed consent language for data and biospecimen sharing.[2] Respondents interested in consent for data and biospecimen sharing may wish to review and comment in response to that RFI.

The NIH seeks comments on any or all of, but not limited to, the following topics:

General opportunities for streamlining access to controlled data

  • Identify the minimum data elements necessary for review of requests to access controlled data from a repository and envision how they may be standardized across repositories.
  • Describe methods to streamline access requests for researchers from one or more institutions collaborating on a single project, while mindful of oversight and accountability.
  • Describe experiences with Institutional Signing Official (ISO) involvement and envision what could be automated to support ISO involvement.
  • Identify potential opportunities to automate elements of data access requests. Describe whether or the extent to which such automation might inherently increase the risk that a request is approved (or recommended for approval) that otherwise should not have been.

Making controlled-access data readily findable and accessible

  • Suggest how to make metadata[3] consistent across repositories to facilitate findability, and how to encourage standard definitions. Describe how frequently standard metadata may need to be updated.
  • Describe your experiences and any barriers that you have experienced with data descriptors such as nomenclatures, search ontologies, etc.
  • Describe what benefits may accrue through the use of standardized data use agreement terms across repositories.
  • Current trends toward "general research use" informed consent language support subsequent broad accessibility of data. However, some research requires more restrictive consents, thus limiting downstream data access. Describe approaches to foster standardized consent language expectations that lead to a common understanding of limitations of data use across repositories. Describe any barriers to researcher acceptance of approaches that might exist.

Addressing oversight, governance, and privacy issues in linking controlled access data from different resources

  • Describe processes for identifying and addressing risks of unanticipated re-identification that may emerge when linking information about a specific person, drawn from two or more datasets from the same, or different repositories with different access processes. Consider whether processes and risk mitigation strategies would differ when the original datasets are controlled vs. open.
    • Describe optimal policy strategies for addressing such risks.
  • Describe processes to ensure there are no gaps in oversight for projects that involve data governed by multiple repositories.
  • Describe strategies that would increase transparency to the public in how data are used.

How to Submit a Response

All comments must be submitted electronically on the Web Portal at: https://datascience.nih.gov/streamlining-access-to-controlled-data-rfi-submission.

Responses

Responses must be received by 11:59:59 pm (ET) on 08/09/21.

Responses to this RFI are voluntary and may be submitted anonymously. You may voluntarily include your name and contact information with your response. If you choose to provide NIH with this information, NIH will not share your name and contact information outside of NIH unless required by law.

Other than your name and contact information, please do not include any personally identifiable information or any information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your response. The Government will use the information submitted in response to this RFI at its discretion. Other than your name and contact information,the Government reserves the right to use any submitted information on public websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding opportunity announcements.This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part of the Government to provide support for any ideas identified in response to it. Please note that the Government will not pay for the preparation of any information submitted or for use of that information.

We look forward to your input and hope that you will share this RFI opportunity with your colleagues.

Reference

[1] https://grants.nih.gov/grants/guide/notice-files/NOT-od-17-044.html.

[2] https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-131.html.

[3] Data that provide additional information intended to make scientific data interpretable and reusable (e.g., date, independent sample and variable construction and description, methodology, data provenance, data transformations, any intermediate or descriptive observational variables). See NIH Policy for Data Management and Sharing at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-013.html.

Inquiries

Please direct all inquiries to:

Vivian OTA WANG PhD
Office of Data Science Strategy
Division of Program Coordination, Planning, and Strategic Initiatives
Office of the Director
Email: streamliningdata-rfi@nih.gov

 The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L